Drug intelligence / Profile preview

VG1198

Development stage: Unknown
Lead developer: VG Life Sciences
Modality: Peptides

Overview

VG1198 is an investigational synthetic peptide developed by VG Life Sciences as part of their peptide platform for potential therapeutic applications. It represents one of three new peptides (VG1196, VG1197, VG1198) recommended by their chemists for laboratory testing, though specific indications, mechanism of action, or clinical data are not publicly detailed beyond early-stage evaluation. The company has highlighted major achievements and new grants supporting their peptide research program.

Beyond the preview

Go deeper on VG1198.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VG1198.

Explore the full profile